Health & Bio

Lilly GLP-1 US market share tops 60%

Mounjaro and Zepbound combined Q sales $12.8B +56% YoY. Lilly now leads globally including ex-US vs Novo Nordisk.

Primary sources · 2
GxP NewsTradingView
Related storylines
#2026-W14-04 · GLP-1 market enters triple inflection point: oral agents, insurance cliff, and end of 503B compounding
← View the full 2026-05-14 (Thu) issue
What you're reading now arrives in your inbox daily at 21:00 UTC.

Get today's brief every day at 21:00 UTC

7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.

Past issues →